Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MDGL save search
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 2.17%
H: 6.03%
C: 2.61%
pharmaceuticals financial results
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: -3.21%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 2.12%
H: 0.7%
C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.34%
H: 1.66%
C: -1.2%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Published: 2024-03-19 (Crawled : 04:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -2.91%
H: 0.61%
C: -3.39%
million offering pharmaceuticals
Madrigal Pharmaceuticals Announces Proposed Public Offering
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -2.91%
H: 0.61%
C: -3.39%
offering pharmaceuticals
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 20.66%
H: 2.07%
C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 0.24%
H: 0.76%
C: -2.7%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.86%
H: 2.04%
C: 1.66%
liver authorization treatment fibrosis pharmaceuticals ema application
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.29%
H: 6.35%
C: 6.33%
year pharmaceuticals financial results
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
SLRN | $4.6 -4.56% -4.78% 2M
|
|
| O: 0.96%
H: 4.63%
C: 0.95%
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.29%
H: 6.35%
C: 6.33%
pharmaceuticals financial
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 21, 2024
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.32%
H: 2.67%
C: -0.32%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.32%
H: 2.67%
C: -0.32%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: -9.47%
publication pharmaceuticals trial
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.82%
H: 1.11%
C: -8.07%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 0.08%
H: 0.92%
C: 0.37%
pharmaceuticals
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $1.47 4.26% 4.08% 71K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $7.56 1.21% 1.19% 3.1M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $8.92 -4.19% -4.37% 750K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: -0.21%
H: 4.06%
C: 3.18%
nasdaq pharmaceuticals grants
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.72%
H: 4.06%
C: 1.22%
conference health pharmaceuticals research
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 22:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.72%
H: 4.06%
C: 1.22%
conference pharmaceuticals
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.